Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management

BACKGROUND: Alemtuzumab is a highly effective therapy for relapsing-remitting multiple sclerosis (RRMS), and immune thrombocytopenia (ITP) has been identified as a risk. OBJECTIVE: To examine ITP incidence, treatment, and outcomes during the clinical development of alemtuzumab for RRMS and discuss p...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuker, Adam, Bass, Ann D, Nadj, Congor, Agius, Mark A, Steingo, Brian, Selmaj, Krzysztof W, Thoits, Timothy, Guerreiro, Alexandre, Van Wijmeersch, Bart, Ziemssen, Tjalf, Meuth, Sven G, LaGanke, Christopher C, Thangavelu, Karthinathan, Rodriguez, Claudio E, Baker, Darren P, Margolin, David H, Jannsens, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950888/
https://www.ncbi.nlm.nih.gov/pubmed/30785358
http://dx.doi.org/10.1177/1352458518816612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950888/
https://www.ncbi.nlm.nih.gov/pubmed/30785358
http://dx.doi.org/10.1177/1352458518816612

Ejemplares similares